Wednesday, 3 October 2018

Cannabidiol

Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol.

http://sci-hub.tw/10.21873/anticanres.12924   (PDF download)
https://www.ncbi.nlm.nih.gov/pubmed/30275207  (abstract at pubmed)

RESULTS:

Clinical responses were seen in 92% of the 119 cases with solid tumours including a reduction in circulating tumour cells in many cases and in other cases, a reduction in tumour size, as shown by repeat scans. No side-effects of any kind were observed when using pharmaceutical grade synthetic cannabidiol.
Posted by at
Labels:

4 comments:

  1. Pedro Xavier3 October 2018 at 17:01

    Thank youThis week In Portugal there was a short and shocking documentary of people desperate in need of CBD but it's illegal to produce and sell. There is a lot of discussion between infarmed that regulates the Portugal industry of pharmaceutical and do it your self.
    https://www.rtp.pt/play/p4231/linha-da-frente
    I read the article. Ty Stephan

    ReplyDelete
  2. Unknown4 October 2018 at 03:27

    What were the doses?

    ReplyDelete
  3. holly84 October 2018 at 08:27

    Interesting that they mentioned using CBD with on and off schedule is beneficial. Anybody see this approach or other evidence somewhere else?
    Holly

    ReplyDelete
  4. Geraldine10 October 2018 at 00:28

    Holly, I am also interested why they are using this pulsed approach. Has anyone come across the clinical evidence for this? Geraldine

    ReplyDelete

Subscribe to: Post Comments (Atom)